Evidence map›Paper›PMID 29531893›Full record

ArticleCurrent epidemiology reports2017

Applying Risk Prediction Models to Optimize Lung Cancer Screening: Current Knowledge, Challenges, and Future Directions.

Lori C Sakoda, Louise M Henderson, Tanner J Caverly, Karen J Wernli, Hormuzd A Katki

Abstract read
In one paragraph

Article in Current epidemiology reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Effects of Personalized Risk Information on Patients Referred for Lung Cancer Screening with Low-Dose CT.Medical decision making : an international journal of the Society for Medical Decision Making · 2019
    Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Lori C SakodaDivision of Research, Kaiser Permanente Northern California, Oakland, CA USA.
Louise M HendersonDepartment of Radiology, University of North Carolina School of Medicine, Chapel Hill, NC USA.
Tanner J CaverlyCenter for Clinical Management Research, Veteran Affairs Ann Arbor Healthcare System, Ann Arbor, MI USA.
Karen J WernliKaiser Permanente Washington Health Research Institute, Seattle, WA USA.
Hormuzd A KatkiDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD USA.

Funding

Methods for Epidemiology StudiesZIACP010181 · NCI · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · PI ALBERT, PAUL · 2009 to 2025
$34.8M
Evaluating a Risk Prediction Model for Lung CancerK07CA188142 · NCI · KAISER FOUNDATION RESEARCH INSTITUTE · PI SAKODA, LORI · 2015 to 2019
$920k
NCI NIH HHS K07 CA188142
6 · The paper itself

Abstract

purpose of reviewRisk prediction models may be useful for facilitating effective and high-quality decision-making at critical steps in the lung cancer screening process. This review provides a current overview of published lung cancer risk prediction models and their applications to lung cancer screening and highlights both challenges and strategies for improving their predictive performance and use in clinical practice. RECENT

findingsSince the 2011 publication of the National Lung Screening Trial results, numerous prediction models have been proposed to estimate the probability of developing or dying from lung cancer or the probability that a pulmonary nodule is malignant. Respective models appear to exhibit high discriminatory accuracy in identifying individuals at highest risk of lung cancer or differentiating malignant from benign pulmonary nodules. However, validation and critical comparison of the performance of these models in independent populations are limited. Little is also known about the extent to which risk prediction models are being applied in clinical practice and influencing decision-making processes and outcomes related to lung cancer screening. SUMMARY: Current evidence is insufficient to determine which lung cancer risk prediction models are most clinically useful and how to best implement their use to optimize screening effectiveness and quality. To address these knowledge gaps, future research should be directed toward validating and enhancing existing risk prediction models for lung cancer and evaluating the application of model-based risk calculators and its corresponding impact on screening processes and outcomes.

Indexed as

lung cancerlung cancer screeningpulmonary nodulesRisk prediction models

Identifiers

PMID29531893
PMCPMC5844483

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.